Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp).
The virus is incapable of developing resistance to favipiravir even with long-term exposure on infected cells, as has been confirmed
On Monday, Moderna Inc (MRNA.O) said its COVID-19 vaccine which generated a strong immune response in children aged six to 11 years and that it plans to submit the data to global regulators soon. Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and
Vaccines for kids between the ages of 5 and 11 will likely be available in the first half of November, top U.S. infectious disease expert Anthony Fauci said on Sunday, predicting a timetable that could see many kids getting fully vaccinated before the end of
On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) recommended the COVID-19 vaccine boosters for recipients of the Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N) shots, and said Americans can choose a different shot from their original inoculation as a booster.
US Pharma giant Pfizer is in the final stages of an agreement with India to supply anti-COVID-19 vaccines, CEO Dr Albert Bourla said on Tuesday, observing that the domestically manufactured vaccines would be the backbone of vaccinating the Indian people. Addressing the 15th edition of
Asserting that India is on track to vaccinate its entire adult population by December, top officials sources on Monday said a blueprint is in place to ensure a total supply of 187.2 crore doses by the year-end that would be enough for the country’s 94
The World Health Organisation (WHO) said on Tuesday that it has approved China’s second COVID-19 vaccine ‘Sinovac’ for emergency use listing.
“WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for
Vaccine, being a biological product, takes time for harvesting and quality testing and this cannot be done overnight to ensure a safe product, the Union Health Ministry said on Friday.
The ministry said Government of India, through the National Expert Group on Vaccine Administration for COVID-19
The government is examining Pfizer’s request for indemnity and will take a decision in the larger interest of people and on merit, NITI Aayog Member (Health) V K Paul said on Thursday.
At a press conference, Paul said, “Yes we are engaged with Pfizer and they